Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06315400
Status:
RECRUITING
Last Update Posted:
2024-04-01
First Post:
2024-03-11
Brief Title:
Efficacy and Safety of Ingavirin Capsules 60 mg in Children With Influenza and Other Acute Respiratory Viral Infections
Sponsor:
Valenta Pharm JSC
Organization:
Valenta Pharm JSC
Study Overview
Official Title:
Double-blind Multicenter Randomized Placebo-controlled Study to Investigate the Efficacy Safety and Tolerability of Ingavirin 60 mg Capsules in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Children Aged 13-17 Years
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin capsules 60 mg in the treatment of influenza or other acute respiratory infections in children from 13 to 17 years compared with placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None